Is Anxious-Agitated Major Depression Responsive to Fluoxetine? A Double-Blind Comparison with Amitriptyline
The DOI matches its Crossref record.
Abstract
Whether fluoxetine (FX) is effective in the treatment of anxious depression is still debated. In the present study, after one week of placebo (single blind), 142 outpatients affected by major depression with relevant anxiety and agitation were randomly assigned (double blind) to either FX (20 mg/day) (n. 67) or amitriptyline (AM) (daily dose: 115+/-39.2mg) (n.75) for a period of 10 weeks. Between groups, the mean score of Hamilton Rating Scale for Depression (HRSD) was significantly different only after 3 weeks of treatment (AM 14.7+/-5.7 vs FX 17.3+/-6.2 (p = 0.02), whereas at the end of the trial it was similar (AM 8.15+/-6.9; FX 8.96+/-6.6). At each visit, no significant difference between groups was found regarding the scores of the HRSD items "psychic anxiety", "somatic anxiety", "agitation". Furthermore, the FIX treatment did not increase the scores of the items "suicide", "psychic anxiety", "somatic anxiety", "agitation" and "insomnia". These findings suggest that patients affected by major depression with anxiety and/or agitation were effectively and safely treated with FX without increasing risks.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In fact, of 10 such studies that compared the effects of serotonergic antidepressants to noradrenergic antidepressants on suicidal ideation, five studies favored serotonergic drugs 316-320 , one study favored a noradrenergic drug 321 , and four studies found no difference 322-325 .”
From Suicide and suicide risk (2019) · cites this paper as [320]
Citations
Cites
Still being checked.
Cited by
Turecki, G., Brent, D. A., Gunnell, D., O’Connor, R. C., Oquendo, M. A., Pirkis, J., & Stanley, B. H. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0121-0 · Cited by 1,074
Guaiana, G., Barbui, C., & Hotopf, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004186.pub2 · Cited by 271
Fluoxetine versus other types of pharmacotherapy for depression
Magni, L. R., Purgato, M., Gastaldon, C., Papola, D., Furukawa, T. A., Cipriani, A., & Barbui, C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004185.pub3 · Cited by 252
Barbui, C., & Hotopf, M. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.2.129 · Cited by 182
Fluoxetine versus other types of pharmacotherapy for depression
Cipriani, A., Brambilla, P., Furukawa, T. A., Geddes, J., Gregis, M., Hotopf, M., Malvini, L., & Barbui, C. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004185.pub2 · Cited by 129
Mixed depressive states: Nosologic and therapeutic issues
Koukopoulos, A., Albert, M. J., Sani, G., Koukopoulos, A. E., & Girardi, P. (2005) · International Review of Psychiatry · doi:10.1080/09540260500064744 · Cited by 91
Barbui, C., Hotopf, M., Freemantle, N., Boynton, J., Churchill, R., Eccles, M., Geddes, Jr., Hardy, R., Lewis, G., & Mason, J. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002791 · Cited by 86
RetractedGrunebaum, M. F., Ellis, S. P., Duan, N., Burke, A. K., Oquendo, M. A., & John Mann, J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.247 · Cited by 79
"Wish Bias" in Antidepressant Drug Trials?
Barbui, C., Cipriani, A., Brambilla, P., & Hotopf, M. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000115665.45074.0d · Cited by 64
Defining anxious depression: going beyond comorbidity
Silverstone, P. H., & von Studnitz, E. (2003) · The Canadian Journal of Psychiatry · doi:10.1177/070674370304801006 · Cited by 57
Pharmacologic Treatment of Dimensional Anxious Depression: A Review
Ionescu, D. F., Niciu, M. J., Richards, E. M., & Zarate, C. A. (2014) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.13r01621 · Cited by 56
Amitriptyline versus other types of pharmacotherapy for depression
Guaiana, G., Barbui, C., & Hotopf, M. (2003) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004186 · Cited by 54
Barbui, C., Hotopf, M., Freemantle, N., Boynton, J., Churchill, R., Eccles, M., Geddes, J., Hardy, R., Lewis, G., & Mason, J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002791.pub2 · Cited by 47
Fluoxetine: A Review of its Use in Anxiety Disorders and Mixed Anxiety and Depression
Hurst, M., & Lamb, H. M. (2000) · CNS Drugs · doi:10.2165/00023210-200014010-00005 · Cited by 40
Fluoxetine treatment of depressed patients with comorbid anxiety disorders
Sonawalla, S. B., Farabaugh, A., Johnson, M. W., Morray, M., Delgado, M. L., Pingol, M. G., Rosenbaum, J. F., & Fava, M. (2002) · Journal of Psychopharmacology · doi:10.1177/026988110201600304 · Cited by 23
Noradrenergic dysfunction and antidepressant treatment response
Corrêa, H., Duval, F., Mokrani, M., Bailey, P., Trémeau, F., Diep, T. S., Crocq, M., Castro, J. O., & Macher, J. P. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(01)00079-7 · Cited by 19
Are SSRIs Really More Effective for Anxious Depression?
Panzer, M. J. (2005) · Annals of Clinical Psychiatry · doi:10.1080/10401230590905317 · Cited by 23
Fluoxetine Alone in the Treatment of First Episode Anxious-Depression: An Open Clinical Trial
Spalletta, G., Pasini, A., & Caltagirone, C. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200206000-00006 · Cited by 10
International Dosage Differences in Fluoxetine Clinical Trials
Patten, S. B., Cipriani, A., Brambilla, P., Nosè, M., & Barbui, C. (2005) · The Canadian Journal of Psychiatry · doi:10.1177/070674370505000107 · Cited by 9
Cheung, C. P., Thiyagarajah, M. T., Abraha, H. Y., Liu, C. S., Lanctôt, K. L., Kiss, A., Saleem, M., Juda, A., LEVITT, A. J., Schaffer, A., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.004 · Cited by 7
Price, D. W. (2002) · The Permanente Journal · doi:10.7812/tpp/02.995 · Cited by 4
Akkaya, C. (2006) · PubMed · Cited by 2
Mahdieh, M. A., Sanati, M. H., Ghaeli, P., Khalili, H., Khansari, H., Alimadadi, A., Abbasiasl, M. R., & Rastgarpanah, M. (2008) · Iranian Journal of Psychiatry · Cited by 3
Current therapeutic strategies for anxious depressives
Silverstone, P. H., von Studnitz, E., & Buller, R. (2003) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.3.2.193 · Cited by 1
Metadata
- Authors
- Marchesi, C., Ceccherininelli, A., Rossi, A., & Maggini, C.
- Affiliations
- University of Parma (IT)
- Eli Lilly (Italy) (IT)
- ORCID
- Rossi, A.
- Venue
- Pharmacopsychiatry
- Publisher
- Georg Thieme Verlag KG
- Published
- 1998-11
- Volume
- 31
- Issue
- 06
- Pages
- 216-221
- ISSN
- 0176-3679 (ISSN-L)
- 1439-0795
- OpenAlex
- W1996503099
- Cited by
- 24
- References
- 0
- Citations by year
- 2020: 1 · 2019: 1 · 2014: 1 · 2013: 1
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacopsychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- anxious depression, major depressive disorder, fluoxetine, amitriptyline, agitation, anxiety, antidepressant efficacy, antidepressant safety, suicide risk, insomnia
- MeSH terms
- Adult, Amitriptyline, Antidepressive Agents, Tricyclic, Anxiety Disorders, Depressive Disorder, Double-Blind Method, Female, Fluoxetine, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.